Tag: corbus

March 12, 2018

Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update

Corbus Pharmaceuticals (NASDAQ: CRBP) a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat...
January 31, 2018

Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design

Corbus Pharmaceuticals (NASDAQ: CRBP) a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced that...
December 22, 2017

Corbus Pharmaceuticals Kicks Off Phase 2 Study

Corbus Pharmaceuticals Holdings announced the start of their phase 2 clinical study of anabasum, treating systemic lupus erythematosus.
December 14, 2017

Corbus Kicks Off Phase 3 Study RESOLVE-1

Corbus Pharmaceuticals Holdings announced it started their Phase 3 study for the efficacy and safety of anabasum in the treatment...
November 27, 2017

Corbus Gets Patent Covering Use of Anabasum for the Treatment of Rare Fibrotic Diseases

Corbus Pharmaceuticals announced it received a patent from the US Patent and Trademark Office covering the use of pharmaceutical compositions...
November 8, 2017

Corbus Reports 2017 Third Quarter Financial Results

Corbus Pharmaceuticals Holdings released their financial report for the third quarter of 2017.
October 31, 2017

Corbus Pharmaceuticals Obtains New US Patent

Corbus Pharmaceuticals Holdings received a patent confirmation for their claim of using pharmaceutical compositions comprising anabasum.